Comparative Analysis of Survival in Pulmonary Arterial Hypertension for Patients Treated with Selexipag in Clinical Practice (EXPOSURE Study), Drugs-Real World Outcomes, April 30, 2025

The EXPOSURE study compared survival rates between pulmonary arterial hypertension (PAH) patients newly treated with selexipag versus other pulmonary arterial hypertension-specific therapies. Survival analyses in EXPOSURE suggest a reduced risk of mortality among the cohort of patients newly initiated on selexipag compared with the modelled cohort newly initiated with other pulmonary arterial hypertension-specific therapies. Further […]

Comparative Analysis of Survival in Pulmonary Arterial Hypertension for Patients Treated with Selexipag in Clinical Practice (EXPOSURE Study), Drugs-Real World Outcomes, April 30, 2025 Read Post »

“Beyond Survival: 11 Years, 2 Lung Transplants, and the Quiet Miracle of Breathing”, Alena Adarbehova

Alena’s journey transcends ordinary resilience. After battling pulmonary hypertension for a decade, surviving two double lung transplants, and undergoing over 200 photopheresis sessions, she now embraces life with just 34% lung function—yet lives it fully. Her story bridges cultures, identities, and the profound gift of donated organs. As she marks 11 years since her first

“Beyond Survival: 11 Years, 2 Lung Transplants, and the Quiet Miracle of Breathing”, Alena Adarbehova Read Post »

Expert Consensus on Lung Transplantation for Pulmonary Arterial Hypertension Patients, Pulmonary Circulation, April 23, 2025

Globally, over 4,500 lung transplants are performed annually. Pulmonary Arterial Hypertension represents a unique transplantation indication because: Given these specific challenges, the authors developed guidelines for managing Pulmonary Arterial Hypertension patients who are lung transplant candidates through a modified Delphi study. The expert panel reached unanimous consensus on several key aspects of lung transplantation for

Expert Consensus on Lung Transplantation for Pulmonary Arterial Hypertension Patients, Pulmonary Circulation, April 23, 2025 Read Post »

Exploring the relationship between sleep difficulties, worry, mood and health-related quality of life in adults living with pulmonary hypertension, a study by researchers at the University of Sheffield, UK

Sleep difficulties are commonly reported by individuals living with pulmonary hypertension (PH); however, there is limited research examining their impact. In other chronic health conditions, sleep problems can affect health-related quality of life and mental wellbeing, potentially increasing the likelihood of experiencing anxiety and low mood. Establishing this relationship in adults with pulmonary hypertension could

Exploring the relationship between sleep difficulties, worry, mood and health-related quality of life in adults living with pulmonary hypertension, a study by researchers at the University of Sheffield, UK Read Post »

Mental Health Awareness Week in the UK (12-18 May): Discover Support Resources from the UK Pulmonary Hypertension Association for Patients and Families

This week (12th-18th May) is Mental Health Awareness Week in the UK. Over the years the UK pulmonary hypertension association, PHA UK, has built up a range of services and resources to help patients that are struggling with anxiety, depression, or general mental wellbeing, you can find all the details at here.

Mental Health Awareness Week in the UK (12-18 May): Discover Support Resources from the UK Pulmonary Hypertension Association for Patients and Families Read Post »

Algorithm provides offers a noninvasive, point-of-care option for detecting pulmonary hypertension, Pulmonary Hypertension News, May 12, 2025

Early diagnosis of pulmonary hypertension has become critical now that effective treatment options exist. A study has shown that Corvista Health’s machine-learned algorithm can accurately diagnose pulmonary hypertension in a non-invasive way by assessing the elevation of mean pulmonary arterial pressure (mPAP). This system could potentially transform the approach to pulmonary hypertension diagnosis as a

Algorithm provides offers a noninvasive, point-of-care option for detecting pulmonary hypertension, Pulmonary Hypertension News, May 12, 2025 Read Post »

A pivotal study is evaluating the validity of a non invasive diagnostic test for pulmonary hypertension as a possible alternative to right heart catheterization

A pivotal study is evaluating a non-evasive device, the Cardiac Performance System, (CPS), for pulmonary hypertension (PH) to reduce reliance on right heart catheterization. The study will compare the measurements obtained with the Cardiac Performance System with those obtained through right heart catheterization, the current gold-standard test used to measure pulmonary artery pressure. If validated,

A pivotal study is evaluating the validity of a non invasive diagnostic test for pulmonary hypertension as a possible alternative to right heart catheterization Read Post »

The importance of respectful language to enhance care, Joint Statement by the Association of Cardiovascular Nurses & Allied Professions (ACNAP), the ESC Patient Forum & the ESC Advocacy Committee, European Journal of Cardiovascular Nursing, April 11, 2025

This statement highlights the vital role of respectful and inclusive language in cardiovascular care. It emphasizes that the way healthcare professionals communicate can significantly influence patient experiences, trust, engagement, treatment adherence, and overall health outcomes. Language that is stigmatizing, dismissive, or judgmental – whether international or unconscious – can cause harm, reinforce inequalities, and discourage

The importance of respectful language to enhance care, Joint Statement by the Association of Cardiovascular Nurses & Allied Professions (ACNAP), the ESC Patient Forum & the ESC Advocacy Committee, European Journal of Cardiovascular Nursing, April 11, 2025 Read Post »

“Global Voices, One Mission: Amplify the Beat” – our motto for the 2025 edition of World Pulmonary Hypertension Day, May 5

Since its inception in 2012, World Pulmonary Hypertension Day (May 5th) has evolved into a powerful global movement uniting patients, caregivers, healthcare professionals, and advocates across continents. What began as a coordinated effort to raise awareness about this rare and serious condition has grown into an international platform for education, advocacy, and community building. World

“Global Voices, One Mission: Amplify the Beat” – our motto for the 2025 edition of World Pulmonary Hypertension Day, May 5 Read Post »

New study explores whether the withdrawal of prostacyclin therapies is possible after initiation of sotatercept, European Respiratory Journal 2025

Prostacyclin therapies, for pulmonary arterial hypertension, especially the parenteral ones, are associated with treatment burden, risks, and high costs. Authors Karen M Olsson, Jan Fuge, Da-Hee Park,Jan C. Kamp, and Marius M. Hoeper have investigated this possibility in a small series of pulmonary arterial hypertension patients treated with sotatercept. Withdrawal of selexipag was found safe,

New study explores whether the withdrawal of prostacyclin therapies is possible after initiation of sotatercept, European Respiratory Journal 2025 Read Post »

Tacrolimus versus cyclosporine immunosuppression in lung transplantation: a systematic review and meta-analysis, BMJ Open Respiratory Research, April 2025

A systematic review and meta-analysis to determine whether tacrolimus or cyclosporine is more effective at reducing chronic lung allograft dysfunction (CLAD) in lung transplant patients was publshed on the British Medical Journal in April 2025. The researchers analyzed 4 randomized trials involving 662 patients with a mean age of 45-55 years, mostly with Chronic Obstructive

Tacrolimus versus cyclosporine immunosuppression in lung transplantation: a systematic review and meta-analysis, BMJ Open Respiratory Research, April 2025 Read Post »

Societal Costs Associated With Pulmonary Arterial Hypertension Subgroups: A Study Utilizing Linked National Registries, Pulmonary Circulation, April 17, 2025

Pulmonary arterial hypertension (PAH) represents a significant economic burden on society, as revealed by a comprehensive Swedish study published on Pulmonary Circulation on April 17, 2025, examining the societal costs associated with this condition. The research tracked patients across various pulmonary arterial hypertension subgroups—idiopathic/hereditary pulmonary arterial hypertension, pulmonary arterial hypertension associated with connective tissue disease,

Societal Costs Associated With Pulmonary Arterial Hypertension Subgroups: A Study Utilizing Linked National Registries, Pulmonary Circulation, April 17, 2025 Read Post »

Physical Activity, Sleep, and Quality of Life in Pulmonary Arterial Hypertension: Novel Insights From Wearable Devices, Pulmonary Circulation, April 16, 2025

A study published in Pulmonary Circulation on April 16, 2025 investigated whether Fitbit wearable devices can provide meaningful clinical information about activity and sleep patterns in pulmonary arterial hypertension (PAH) patients. A total of 110 participants completed the 12-week baseline monitoring period. The cohort was median age 52.7 years (IQR: 40.9–60.5), female predominant (84% female),

Physical Activity, Sleep, and Quality of Life in Pulmonary Arterial Hypertension: Novel Insights From Wearable Devices, Pulmonary Circulation, April 16, 2025 Read Post »

“A wake-up call: key trends and policy asks for cardiovascular health in women”, European Parliament event, March 5, 2025

We were unfortunately unable to attend the European Parliament event which took place on March 5, 2025, but have read the minutes with great interest. Based on these we have put together some key takeaways as this topic is very relevant to pulmonary arterial hypertension patients, who are predominantly women. Opening Member of the European

“A wake-up call: key trends and policy asks for cardiovascular health in women”, European Parliament event, March 5, 2025 Read Post »

Balloon Pulmonary Angioplasty (BPA)’s development from its early applications to its current widespread adoption globally, Expert Review of Respiratory Medicine, April 14, 2025

Balloon Pulmonary Angioplasty (BPA) has revolutionized treatment for Chronic Thromboembolic Pulmonary Hypertension (CTEPH), as discussed in a comprehensive review published on April 14 2025 in the Expert Review of Respiratory Medicine. While Pulmonary Endarterectomy (PEA) continues to be the gold standard for patients with operable disease, many patients cannot undergo this surgical procedure due to

Balloon Pulmonary Angioplasty (BPA)’s development from its early applications to its current widespread adoption globally, Expert Review of Respiratory Medicine, April 14, 2025 Read Post »

Liberal fluid intake versus fluid restriction in chronic heart failure: a randomized clinical trial, Nature Medicine, March 30, 2025

A major study, led by the Radboud university medical center in the Netherlands, has shown that fluid restriction in people with stable heart failure offers no health benefits. On the contrary: it mainly causes thirst and discomfort. Whether patients drink less or not, there are no differences in overall health, hospital admissions, mortality, or medication

Liberal fluid intake versus fluid restriction in chronic heart failure: a randomized clinical trial, Nature Medicine, March 30, 2025 Read Post »

Pulmonary Artery Denervation (PADN) shows promise as a novel therapeutic approach in pulmonary hypertension, International Journal of Cardiology, May 2025 edition

Pulmonary Artery Denervation (PADN) shows promise as a novel therapeutic approach targeting the sympathetic nervous system’s role in pulmonary hypertension, reveal the findings of a metanalysis reviewing 14 studies, involving 372 patients. Pulmonary Artery Denervation improved several key hemodynamic parameters and clinical outcomes. The meta-analysis was published in the May 2025 edition of the International Journal

Pulmonary Artery Denervation (PADN) shows promise as a novel therapeutic approach in pulmonary hypertension, International Journal of Cardiology, May 2025 edition Read Post »

Medication adherence and clinical outcomes in patients with pulmonary arterial hypertension or distal chronic thromboembolic pulmonary hypertension, British Medical Journal Open Respiratory Research, April 5, 2025

The findings of a prospective study on 93 patients (66% women, 75% PAH, 25% CTEPH, 57±17 years), all on pulmonary hypertension-targeted oral medication, between 2013 and 2023, were recently published in the British Medical Journal Open Respiratory Research. These reveal that mean MPR (Medication Possession Ratio) and self-reported adherence were overall high, with 78% of patients

Medication adherence and clinical outcomes in patients with pulmonary arterial hypertension or distal chronic thromboembolic pulmonary hypertension, British Medical Journal Open Respiratory Research, April 5, 2025 Read Post »

Pulmonary arterial hypertension in Latin America. The age and comorbidity paradox, International Journal of Cardiology Congenital Heart Disease, March 2025

Pulmonary arterial hypertension (PAH), once seen mostly in young, healthy women, is now common among older adults with comorbidities in North America and Europe. In contrast, Latin American patients remain younger and healthier, with fewer related conditions. Possible Reasons Current Situation Latin American pulmonary arterial hypertension patients have: Future Concerns Rising obesity and aging populations

Pulmonary arterial hypertension in Latin America. The age and comorbidity paradox, International Journal of Cardiology Congenital Heart Disease, March 2025 Read Post »

Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death, New England Journal of Medicine, March 31, 2025

An article published in the New England Journal of Medicine on March 31 titled “Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death” reports on the findings of ZENITH, a phase 3 trial which evaluated sotatercept as an add-on therapy for high-risk pulmonary arterial hypertension patients (functional class II-IV) already on maximum

Sotatercept in Patients with Pulmonary Arterial Hypertension at High Risk for Death, New England Journal of Medicine, March 31, 2025 Read Post »

TRANSLATE »
Scroll to Top